Drug combination therapy plays a vital role in disease treatment, including cancer, as it contributes to treatment efficacy and can alleviate the effect of drug resistance. Although clinical trials and screening may provide valuable information about synergistic drug combinations, they suffer from challenging combinatorial space. Multiple methods are proposed to address those issues. However, they still fail in making full use of global and local triplet context relationships of known synergistic combinations. To this end, a deep learning model which leverages dual view hypergraph representation fusion for synergistic drug combinations identification is proposed, namely DVHSyn. It first extracts the transcriptome features of cancer cell lines and molecular structures of drugs. Subsequently, by modeling the synergistic effect on a hypergraph, DVHSyn simultaneously learns the local and global context of the sample triplets via a hypergraph view and its expanded heterogeneous graph view. Finally, the learned representations of the above two branches are fused selectively to predict synergistic drug combinations. Experiment results demonstrate that DVHSyn surpasses six other competing methods. One case study also reflects that DVHSyn has the potential to predict novel synergistic drug combinations. Overall, our method is effective in identifying synergistic drug combinations and provides new insights for novel drug development.

Bioactive peptide therapeutics has been a long-standing research topic. Notably, the antimicrobial peptides (AMPs) have been extensively studied for its therapeutic potential. Meanwhile, the demand for annotating other therapeutic peptides, such as antiviral peptides (AVPs) and anticancer peptides (ACPs), also witnessed an increase in recent years. However, we conceive that the structure of peptide chains and the intrinsic information between the amino acids is not fully investigated among the existing protocols. Therefore, we develop a new graph deep learning model, namely TP-LMMSG, which offers lightweight and easy-to-deploy advantages while improving the annotation performance in a generalizable manner. The results indicate that our model can accurately predict the properties of different peptides. The model surpasses the other state-of-the-art models on AMP, AVP and ACP prediction across multiple experimental validated datasets. Moreover, TP-LMMSG also addresses the challenges of time-consuming pre-processing in graph neural network frameworks. With its flexibility in integrating heterogeneous peptide features, our model can provide substantial impacts on the screening and discovery of therapeutic peptides. The source code is available at https://github.com/NanjunChen37/TP_LMMSG.

Protein acetylation is one of the extensively studied post-translational modifications (PTMs) due to its significant roles across a myriad of biological processes. Although many computational tools for acetylation site identification have been developed, there is a lack of benchmark dataset and bespoke predictors for non-histone acetylation site prediction. To address these problems, we have contributed to both dataset creation and predictor benchmark in this study. First, we construct a non-histone acetylation site benchmark dataset, namely NHAC, which includes 11 subsets according to the sequence length ranging from 11 to 61 amino acids. There are totally 886 positive samples and 4707 negative samples for each sequence length. Secondly, we propose TransPTM, a transformer-based neural network model for non-histone acetylation site predication. During the data representation phase, per-residue contextualized embeddings are extracted using ProtT5 (an existing pre-trained protein language model). This is followed by the implementation of a graph neural network framework, which consists of three TransformerConv layers for feature extraction and a multilayer perceptron module for classification. The benchmark results reflect that TransPTM has the competitive performance for non-histone acetylation site prediction over three state-of-the-art tools. It improves our comprehension on the PTM mechanism and provides a theoretical basis for developing drug targets for diseases. Moreover, the created PTM datasets fills the gap in non-histone acetylation site datasets and is beneficial to the related communities. The related source code and data utilized by TransPTM are accessible at https://www.github.com/TransPTM/TransPTM.

As a major component of online crime, email-based fraud is a threat that causes substantial economic losses every year. To counteract these scammers, volunteers called scam-baiters play the roles of victims, reply to scammers, and try to waste their time and attention with long and unproductive conversations. To curb email fraud and magnify the effectiveness of scam-baiting, we developed and deployed an expandable scam-baiting mailserver that can conduct scam-baiting activities automatically. We implemented three reply strategies using three different models and conducted a one-month-long experiment during which we elicited 150 messages from 130 different scammers. We compare the performance of each strategy at attracting and holding the attention of scammers, finding tradeoffs between human-written and automatically-generated response strategies. We also demonstrate that scammers can be engaged concurrently by multiple servers deploying these strategies in a second experiment, which used two server instances to contact 92 different scammers over 12 days. We release both our platform and a dataset containing conversations between our automatic scam-baiters and real human scammers, to support future work in preventing online fraud.

The rapid growth of omics-based data has revolutionized biomedical research and precision medicine, allowing machine learning models to be developed for cutting-edge performance. However, despite the wealth of high-throughput data available, the performance of these models is hindered by the lack of sufficient training data, particularly in clinical research (in vivo experiments). As a result, translating this knowledge into clinical practice, such as predicting drug responses, remains a challenging task. Transfer learning is a promising tool that bridges the gap between data domains by transferring knowledge from the source to the target domain. Researchers have proposed transfer learning to predict clinical outcomes by leveraging pre-clinical data (mouse, zebrafish), highlighting its vast potential. In this work, we present a comprehensive literature review of deep transfer learning methods for health informatics and clinical decision-making, focusing on high-throughput molecular data. Previous reviews mostly covered image-based transfer learning works, while we present a more detailed analysis of transfer learning papers. Furthermore, we evaluated original studies based on different evaluation settings across cross-validations, data splits and model architectures. The result shows that those transfer learning methods have great potential; high-throughput sequencing data and state-of-the-art deep learning models lead to significant insights and conclusions. Additionally, we explored various datasets in transfer learning papers with statistics and visualization.

MOTIVATION: Single-cell RNA sequencing (scRNA-seq) can provide insight into gene expression patterns at the resolution of individual cells, which offers new opportunities to study the behavior of different cell types. However, it is often plagued by dropout events, a phenomenon where the expression value of a gene tends to be measured as zero in the expression matrix due to various technical defects. RESULTS: In this article, we argue that borrowing gene and cell information across column and row subspaces directly results in suboptimal solutions due to the noise contamination in imputing dropout values. Thus, to impute more precisely the dropout events in scRNA-seq data, we develop a regularization for leveraging that imperfect prior information to estimate the true underlying prior subspace and then embed it in a typical low-rank matrix completion-based framework, named scWMC. To evaluate the performance of the proposed method, we conduct comprehensive experiments on simulated and real scRNA-seq data. Extensive data analysis, including simulated analysis, cell clustering, differential expression analysis, functional genomic analysis, cell trajectory inference and scalability analysis, demonstrate that our method produces improved imputation results compared to competing methods that benefits subsequent downstream analysis. AVAILABILITY AND IMPLEMENTATION: The source code is available at https://github.com/XuYuanchi/scWMC and test data is available at https://doi.org/10.5281/zenodo.6832477. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Obtaining discriminative features is one of the key problems in three-dimensional (3D) shape retrieval. Recently, deep metric learning-based 3D shape retrieval methods have attracted the researchers’ attention and have achieved better performance. The triplet-center loss can learn more discriminative features than traditional classification loss, and it has been successfully used in deep metric learning-based 3D shape retrieval task. However, it has a hard margin parameter that only leverages part of the training data in each mini-batch. Moreover, the margin parameter is often determined by experience and remains unchanged during the training process. To overcome the above limitations, we propose the soft margin triplet-center loss, which replaces the margin with the nonparametric soft margin. Furthermore, we combined the proposed soft margin triplet-center loss with the softmax loss to improve the training efficiency and the retrieval performance. Extensive experimental results on two popular 3D shape retrieval datasets have validated the effectiveness of the soft margin triplet-center loss, and our proposed 3D shape retrieval method has achieved better performance than other state-of-the-art method.

Exploring the prognostic classification and biomarkers in Head and Neck Squamous Carcinoma (HNSC) is of great clinical significance. We hybridized three prominent strategies to comprehensively characterize the molecular features of HNSC. We constructed a 15-gene signature to predict patients' death risk with an average AUC of 0.744 for 1-, 3-, and 5-year on TCGA-HNSC training set, and average AUCs of 0.636, 0.584, 0.755 in GSE65858, GSE-112026, CPTAC-HNSCC datasets, respectively. By combined with NMF clustering and consensus clustering of fraction of tumor immune cell infiltration (ICI) in the tumor microenvironment (TME), we captured a more refined biological characteristics of HNSC, and observed a prognosis heterogeneity in high tumor immunity patients. By matching tumor subset-specific expression signatures to drug-induced cell line expression profiles from large-scale pharmacogenomic databases in the OCTAD workspace, we identified a group of HNSC patients featured with poor prognosis and demonstrated that the individuals in this group are likely to receive increased drug sensitivity to reverse differentially expressed disease signature genes. This trend is especially highlighted among those with higher death risk and tumour immunity.

With the great changes in network scale and network topology, the difficulty of DDoS attack detection increases significantly. Most of the methods proposed in the past rarely considered the real-time, adaptive ability, and other practical issues in the real-world network attack detection environment. In this paper, we proposed a real-time adaptive DDoS attack detection method RT-SAD, based on the response to the external network when attacked. We designed a feature extraction method based on sketch and an adaptive updating algorithm, which makes the method suitable for the high-speed network environment. Experiment results show that our method can detect DDoS attacks using sampled Netflowunder high-speed network environment, with good real-time performance, low resource consumption, and high detection accuracy.